Immunohistochemical expression of 14-3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis

被引:25
作者
Mhawech, P
Greloz, V
Assaly, M
Herrmann, F
机构
[1] Univ Hosp Geneva, CMU, Pathol Clin, Dept Pathol, CH-1211 Geneva 4, Switzerland
[2] Univ Hosp Geneva, Dept Rehabil & Geriatr, CH-1211 Geneva 4, Switzerland
关键词
14-3-3; sigma; embryonal carcinoma; kidney neoplasms; prostate; seminoma; urinary bladder;
D O I
10.1111/j.1440-1827.2004.01797.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
14-3-3 sigma is an exclusive epithelial marker and data on its expression in different malignancies are very scarce. The aims of the present study are to screen its expression in the most common neoplasms occurring in the urological and gynecological tract and to evaluate its use as a diagnostic marker. A tissue microarray was constructed using 350 samples from 13 different neoplasms. Immunohistochemical analysis using a polyclonal 14-3-3 sigma antibody was performed. Overall, this protein was positive in 141 and negative in 209 tumors. The most frequent expression was seen in squamous cell carcinoma of the cervix and urothelial bladder carcinoma, followed by prostatic and endometrial adenocarcinoma. 14-3-3 sigma was able to distinguish prostate adenocarcinoma from urothelial bladder carcinoma, with an odds ratio of 0.028 (P = 0.001; 95% CI, 0.0003-0.222), and distinguish seminoma from embryonal carcinoma of the testis, with an odds ratio of 0.061 (P = 0.009; 95% CI, 0.007-0.5014). It also has a good value in differentiating renal clear cell carcinoma from papillary carcinoma, with an odds ratio 0.470 (P < 0.001; 95% CI, 0.008-0.261). 14-3-3 sigma seems to have good potential use as an epithelial marker, after confirmation with further targeted studies. Finally, as with all immunohistochemical markers, we can optimize the utility of this protein to distinguish tumor mimics by including it in an appropriate immunohistochemical panel.
引用
收藏
页码:77 / 82
页数:6
相关论文
共 25 条
[1]   Decreased expression of 14-3-3σ is associated with advanced disease in human epithelial ovarian cancer:: Its correlation with aberrant DNA methylation [J].
Akahira, J ;
Sugihashi, Y ;
Suzuki, T ;
Ito, K ;
Niikura, H ;
Moriya, T ;
Nitta, M ;
Okamura, H ;
Inoue, S ;
Sasano, H ;
Okamura, K ;
Yaegashi, N .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2687-2693
[2]   Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases [J].
Amin, MB ;
Amin, MB ;
Tamboli, P ;
Javidan, J ;
Stricker, H ;
Venturina, MD ;
Deshpande, A ;
Menon, M .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2002, 26 (03) :281-291
[3]   Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma [J].
Bassily, NH ;
Vallorosi, CJ ;
Akdas, G ;
Montie, JE ;
Rubin, MA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (03) :383-388
[4]  
Chan TA, 2000, GENE DEV, V14, P1584
[5]   Loss of 14-3-3σ in prostate cancer and its precursors [J].
Cheng, L ;
Pan, CX ;
Zhang, JT ;
Zhang, SB ;
Kinch, MS ;
Li, L ;
Baldridge, LA ;
Wade, C ;
Hu, ZQ ;
Koch, MO ;
Ulbright, TM ;
Eble, JN .
CLINICAL CANCER RESEARCH, 2004, 10 (09) :3064-3068
[6]   Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma [J].
Cheville, JC ;
Lohse, CM ;
Zincke, H ;
Weaver, AL ;
Blute, ML .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (05) :612-624
[7]   Cytokeratin expression in seminoma of the human testis [J].
Cheville, JC ;
Rao, S ;
Iczkowski, KA ;
Lohse, CM ;
Pankratz, VS .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (04) :583-588
[8]   Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases [J].
Chu, PG ;
Wu, E ;
Weiss, LM .
MODERN PATHOLOGY, 2000, 13 (09) :962-972
[9]  
Gillett CE, 2000, J PATHOL, V192, P549
[10]   Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation [J].
Herman, JG ;
Baylin, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2042-2054